Loxapine Succinate

The green analytical UPLC methods are highly effective for quantifying impurities because these methods reduce the usage of harmful chemicals and generate less waste leading to minimal environmental influence. Currently, there are no green methods reported for quantifying impurities in Loxapine and hence this study plans to fill the gap noticed in the literature. In method optimization, various compositions of green solvents including ethanol, and water with buffers were utilized as mobile phase. The conditions that produce acceptable results were studied for valuation in terms of linearity, accuracy, precision, and sensitivity. This method was applied for the resolution and structural evaluation of degradation products (DPs) of Loxapine using LCMS/MS. The method comprises Waters Acquity UPLC® HSS C18 (2.1mm × 100mm, 1.8µm) column along with ethanol, 0.1M Formic acid in water, and water in 50:20:30 (v/v) at pH 4.8 at 0.75 mL/min flow and 265 nm. All validation parameters were tested, and acceptable results were obtained for Loxapine and its impurities. The stress study identified three separate degradation products in the acid and base degradation chromatograms, labeled DP 1, DP 2, and DP 3. MSn studies and mass fragmentation analysis confirmed DP 1 as 2-chlorodibenzo[b,f][1,4]oxazepin-11(10H)-imine, DP 2 as 3-chloro-N-phenylbenzene carboximidamide and DP 3 as N-(2-chlorodibenzo [b,f][1,4]oxazepin-11-yl) -N-methylethane-1,2-diamine. The Greenness of the method was evaluated using GAPI (Green Analytical Procedure Index) and AGREE (Analytical GREEnness) tools, confirming that this technique can greatly cut down the use of harmful solvents while maintaining good chromatographic results. Hence, this method is effective for evaluating impurities of Loxapine and also characterizing its DPs.

Osteoarthritis is one of the most common locomotor diseases, with a steadily increasing prevalence and incidence. Loxacon^® is a food supplement capsule containing vitamins, minerals, and herbal extracts with Boswellia serrata extract and Harpagophytum procumbens extract as its two main active components. The study involved 88 patients at 4 sites. The 88 patients were divided into 3 groups. The first group received physical therapy and Loxacon^® capsules for 5 weeks, while the second group (30 patients) received physical therapy only for 5 weeks, and the third group (30 patients) received physical therapy and placebo capsules for 5 weeks. After 5 weeks, physical therapy was discontinued in all three groups and all groups continued Loxacon^® capsules exclusively for an additional 60 days. Physical therapy had been carried out by a standard protocol over 5 weeks. Investigated parameters included Western Ontario and McMaster Universities Arthritis Index (WOMAC) testing, European Quality of Life (EQ-5D-5L) quality of life test and the Range of Motion (ROM). Among the 4 visual analogue scale (VAS) values investigated from WOMAC, significant change was seen for functionality in all three groups; however, the extent of change was twice as large in the physical therapy + Loxacon^® group at Visit 2 in comparison with the other two groups. In the physical therapy + placebo group, improvement was seen only at the 3rd visit when they were also receiving Loxacon^® capsules. The most pronounced difference was seen in the minimum clinically important difference index, calculated from the quality of life-VAS, where those taking Loxacon^® capsules had a chance 3 times as high to obtain clinical improvement versus the other two groups. Our study confirmed that a combination of boswellic acid and harpagosides is beneficial as an additional therapy in knee OA.